An Efficient, Simultaneous Electrochemical Assay of Rosuvastatin and Ezetimibe from Human Urine and Serum Samples.
Leyla KaradurmusSevinc KurbanogluBengi UsluSibel Ayşıl ÖzkanPublished in: Methods and protocols (2022)
The drug combination of rosuvastatin (ROS) and ezetimibe (EZE) is used to treat hypercholesterolemia. In this work, a simultaneous electrochemical examination of ROS and EZE was conducted for the first time. The electrochemical determination of ROS and EZE was carried out using adsorptive stripping differential pulse voltammetry (AdSDPV) on a glassy carbon electrode (GCE) in 0.1 M H 2 SO 4 . The effects of the pH, scan rate, deposition potential, and time on the detection of ROS and EZE were analyzed. Under optimum conditions, the developed sensor exhibited a linear response between 1.0 × 10 -6 M and 2.5 × 10 -5 M for EZE and 5.0 × 10 -6 M, and 1.25 × 10 -5 M for ROS. The detection limits for ROS and EZE were 3.0 × 10 -7 M and 2.0 × 10 -6 M, respectively. The developed sensor was validated in terms of linear range, accuracy, precision, the limit of determination (LOD), and the limit of quantification (LOQ), and it was evaluated according to ICH Guidelines and USP criteria. The proposed method was also used to determine ROS and EZE in human urine and serum samples, which are reported in terms of recovery studies.
Keyphrases
- cell death
- dna damage
- reactive oxygen species
- molecularly imprinted
- endothelial cells
- gold nanoparticles
- computed tomography
- ionic liquid
- blood pressure
- magnetic resonance
- risk assessment
- high throughput
- induced pluripotent stem cells
- cardiovascular disease
- cardiovascular events
- coronary artery disease
- human health
- case control
- drug induced